Want to see SERA full AI Analyst Report?
SERA Stock Chart & Stats
$2.30
$0.42(5.34%)
At close: 4:00 PM EST
$2.30
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.56 - $3.95
Previous CloseN/A
Volume57.63K
Average Volume (3M)40.22K
Market Cap
$79.49M
Enterprise Value$70.51M
Total Cash (Recent Filing)$47.40M
Total Debt (Recent Filing)$2.50M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding38,190,968
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)1735.84
P/FCF Ratio-5.34
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.24K
Enterprise Value/Gross Profit-646.89
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$6.00Price Target Upside160.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$415.33K
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA multi-year cash runway ( ~$86.8M ) combined with planned ~ $10M annual opex reductions materially lowers near-term refinancing pressure. That financial flexibility gives management time to execute commercialization, payer wins and regulatory milestones without forcing premature dilution or cuts to core activities.
Commercial And Payer-engagement MomentumBuilding partner programs and expanding payer conversations creates durable distribution and access pathways. A network of live programs, planned quarterly launches, and multi-state payer engagement enhance the company's ability to convert evidence into contracted volume and longer-term recurring testing revenue.
Regulatory And Commercialization Readiness In EuropeProgress toward CE Marking opens a material new commercial geography and validates regulatory readiness. Achieving CE marking would create a durable addressable market outside the U.S., supporting diversified revenue channels and long-term scale if market access and reimbursement follow in key European markets.
Bears Say
Tiny, Declining Revenue And Negative Gross ProfitRevenue has collapsed to immaterial levels and gross profit is negative, indicating the core test is not yet producing scalable, profitable sales. Persistent subscale revenue undermines investment economics and makes it difficult to prove unit economics or justify commercial investments absent clear adoption inflection points.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow show the business is consuming capital to commercialize rather than generating it. Even with a runway, ongoing cash burn increases cumulative financing needs and raises downside risk if commercialization or reimbursement timelines extend beyond expectations.
Slow Payer Coverage And Unclear Near-term Volume VisibilityLengthy payer decision timelines and management's withholding of test-volume KPIs limit visibility into sustainable demand. Delayed coverage slows scaling, delays revenue realization, and makes forecasting and commercialization ROI uncertain, increasing execution risk over the next 2–3 years.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.56 and its highest was $3.95 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $79.49M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Undervalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.15.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,190,968 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 6.077%.
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (160.87% Upside)
$6.00 (160.87% Upside)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $87.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
-41.02%
Trailing 12-Months
Asset Growth
-20.85%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
SERA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong strategic progress on commercialization, payer engagement, media awareness, scientific publications and a clear plan to reduce operating expense that together support a multi-year commercial opportunity. However, near-term financials remain weak — Q1 revenue fell to $14k (down ~63% YoY), a continuing net loss (~$8.4M) and management expects 2026 revenue to be modest and uneven while payer coverage and broader adoption timelines play out. Given meaningful operational and evidence milestones but limited near-term revenue visibility, the tone is cautiously constructive but balanced by financial and timing risks.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
$6.00
▲(160.87% Upside)
Technical Analysis
Ownership Overview
5.29% Insiders
4.07% Mutual Funds
36.09% Other Institutional Investors
50.93% Public Companies and
Individual Investors